1.
Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study.
Khouri Albert S, Serle Janet B, Bacharach Jason, Usner Dale W, Lewis Richard A, Braswell Puiwah et al.
Am J OphthalmolMar 20190 citationsRandomized Controlled Trial
Netarsudil once-daily was noninferior to timolol twice-daily for lowering IOP in glaucoma/ocular hypertension, offering a new effective, tolerable, and convenient treatment option without systemic heart rate effects.